GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cosmo Pharmaceuticals NV (OTCPK:CMOPF) » Definitions » Quick Ratio

CMOPF (Cosmo Pharmaceuticals NV) Quick Ratio : 4.48 (As of Jun. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Cosmo Pharmaceuticals NV Quick Ratio?

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Cosmo Pharmaceuticals NV's quick ratio for the quarter that ended in Jun. 2024 was 4.48.

Cosmo Pharmaceuticals NV has a quick ratio of 4.48. It generally indicates good short-term financial strength.

The historical rank and industry rank for Cosmo Pharmaceuticals NV's Quick Ratio or its related term are showing as below:

CMOPF' s Quick Ratio Range Over the Past 10 Years
Min: 1.11   Med: 10.4   Max: 24.13
Current: 4.48

During the past 13 years, Cosmo Pharmaceuticals NV's highest Quick Ratio was 24.13. The lowest was 1.11. And the median was 10.40.

CMOPF's Quick Ratio is ranked better than
86.96% of 1035 companies
in the Drug Manufacturers industry
Industry Median: 1.4 vs CMOPF: 4.48

Cosmo Pharmaceuticals NV Quick Ratio Historical Data

The historical data trend for Cosmo Pharmaceuticals NV's Quick Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cosmo Pharmaceuticals NV Quick Ratio Chart

Cosmo Pharmaceuticals NV Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Quick Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 18.86 11.34 12.37 1.51 3.42

Cosmo Pharmaceuticals NV Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Quick Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.81 1.51 1.35 3.42 4.48

Competitive Comparison of Cosmo Pharmaceuticals NV's Quick Ratio

For the Drug Manufacturers - General subindustry, Cosmo Pharmaceuticals NV's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cosmo Pharmaceuticals NV's Quick Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cosmo Pharmaceuticals NV's Quick Ratio distribution charts can be found below:

* The bar in red indicates where Cosmo Pharmaceuticals NV's Quick Ratio falls into.



Cosmo Pharmaceuticals NV Quick Ratio Calculation

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.

Cosmo Pharmaceuticals NV's Quick Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Quick Ratio (A: Dec. 2023 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(111.479-15.483)/28.041
=3.42

Cosmo Pharmaceuticals NV's Quick Ratio for the quarter that ended in Jun. 2024 is calculated as

Quick Ratio (Q: Jun. 2024 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(197.625-14.964)/40.773
=4.48

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cosmo Pharmaceuticals NV  (OTCPK:CMOPF) Quick Ratio Explanation

The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.

In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.

The higher the quick ratio, the better the company's liquidity position.


Cosmo Pharmaceuticals NV Quick Ratio Related Terms

Thank you for viewing the detailed overview of Cosmo Pharmaceuticals NV's Quick Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Cosmo Pharmaceuticals NV Business Description

Traded in Other Exchanges
Address
Sir John Rogerson’s Quay, Riverside II, Dublin, IRL, 2
Cosmo Pharmaceuticals NV is a pharmaceutical company with a focus on gastrointestinal diseases, dermatology and healthtech. The company develops and manufactures products that are distributed globally by its partners. Products that the company has developed include Lialda/Mezavant/Mesavancol and Uceris/Cortiment, for the treatment of ulcerative colitis; GI Genius, which uses artificial intelligence to aid the detection of colorectal polyps during colonoscopy; Eleview, a submucosal injectable composition for use in gastrointestinal endoscopic procedures; Aemcolo for the treatment of travellers' diarrhoea (TD) and Winlevi for the treatment of acne. Product pipeline includes Breezula, GI Genius, Methylene blue MMX, Aemcolo, CB-03-10 and CB-01-33.

Cosmo Pharmaceuticals NV Headlines